Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences reported a leadership change affecting its legal and corporate affairs functions. The company announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel as of December 5, 2025. Her employment with the company will end later in December. This transition means Gilead will need to adjust leadership responsibilities in a key oversight and governance role, which can influence how the company manages legal risk, regulatory matters and external corporate communications.
Gilead Sciences, Inc. (GILD) reported an insider transaction by its Chief Financial Officer. On 11/17/2025, the CFO sold 2,500 shares of Gilead common stock at a price of $125.23 per share in an open-market sale coded as an "S" transaction. After this sale, the reporting person beneficially owns 154,555 shares of Gilead common stock in direct ownership. The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, which is designed to allow insiders to trade according to predetermined instructions.
Gilead Sciences, Inc. (GILD) reported insider activity by its Chief Commercial Officer, Johanna Mercier. On 11/17/2025, she exercised a non-qualified stock option to acquire 25,000 shares of common stock at an exercise price of $66.64 per share, increasing her direct holdings before any sales.
That same day, she reported open-market sales of 25,524 shares at a weighted-average price of $125.8251 and 2,476 shares at a weighted-average price of $126.2575, all under a Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, she directly owned 107,193 shares of Gilead common stock and 73,110 non-qualified stock options.
Gilead Sciences (GILD) disclosed insider activity by its EVP, Corporate Affairs & GC, on 11/12/2025 pursuant to a Rule 10b5‑1 trading plan adopted on August 13, 2025. The officer exercised non‑qualified stock options and sold the resulting shares the same day.
Exercises were for 17,181 shares at $75.12, 35,965 shares at $60.75, and 500 shares at $60.75, followed by sales of equal amounts. Sale prices included $124 and weighted‑average prices of $122.302 and $122.904, with transaction ranges of $121.87–$122.83 and $122.88–$122.92. After these trades, 43,676 common shares were beneficially owned directly.
Gilead Sciences, Inc. filed a Form 13F reporting its institutional holdings. The filing is a 13F Holdings Report signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, dated 11-13-2025.
The report lists 9 information-table entries with a total value of $1,791,467,184 and names one other included manager, Gilead Therapeutics A1 Unlimited Co (Form 13F File No. 028-25083).
Gilead Sciences (GILD) filed its Q3 2025 10‑Q, reporting total revenue of $7.77 billion, up from $7.55 billion a year ago, and diluted EPS of $2.43 versus $1.00. Net income rose to $3.05 billion from $1.25 billion as operating income improved to $3.33 billion, reflecting lower charges versus last year and higher royalty and contract revenue.
Product sales were $7.35 billion (slightly below $7.52 billion last year). HIV remained the core driver at $5.28 billion, led by Biktarvy at $3.69 billion. Liver Disease rose to $819 million, while Veklury declined to $277 million. Oncology product sales were $788 million, with Cell Therapy at $432 million and Trodelvy at $357 million. The company recognized $400 million of previously constrained revenue tied to a sale of certain intellectual property, lifting royalty/contract revenue to $424 million. Cash and equivalents were $7.33 billion; operating cash flow for the nine months was $6.69 billion. Shares outstanding were 1,240,679,623 as of October 31, 2025.
Gilead Sciences announced its financial results for the quarter ended September 30, 2025 and furnished a press release as Exhibit 99.1.
The company presented GAAP and non-GAAP measures, with reconciliations provided in the press release tables. The information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated by reference.
Gilead Sciences (GILD) insider filing: Chairman & CEO Daniel P. O’Day reported open‑market sales totaling 10,000 shares on 10/28/2025 under a Rule 10b5‑1 trading plan adopted on February 28, 2025. The transactions were coded “S”.
He sold 7,978 shares at an average price of $119.5371 and 2,022 shares at $118.8223. Following the sales, he beneficially owns 581,203 shares directly, down from 583,225 before these trades. The filing notes price ranges for each trade, with full breakdowns available upon request to the company, the SEC, or shareowners.
Gilead Sciences (GILD): Officer equity transaction reported
On 10/25/2025, an officer of Gilead Sciences (title: EVP, Corporate Affairs & GC) reported the conversion of 515 restricted stock units into common stock (transaction code M) and the disposition of 241 shares at $120.94 (transaction code F). Following these transactions, the officer directly owned 43,676 shares of common stock.
The filing also shows 19,816 restricted stock units beneficially owned after the reported transaction. The RSUs vest over four years: 25% on the first anniversary of grant, then 6.25% quarterly until fully vested.
Gilead Sciences (GILD) CFO Andrew D. Dickinson reported an open‑market sale of 2,500 shares of common stock at $118.08 on October 15, 2025. The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on August 29, 2024.
Following the transaction, Dickinson beneficially owns 157,055 shares, held directly.